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Abstract
Although epidemiological findings support a role for vitamin K status in the improvement of bone indices in adult patients with Crohn’s
disease (CD), this needs to be confirmed in double-blind, randomised controlled trials (RCT) with phylloquinone (vitamin K1). By conduct-
ing two RCT, the present study aimed to first establish whether supplementation with 1000mg of phylloquinone daily near-maximally
suppresses the percentage of undercarboxylated osteocalcin in serum (%ucOC; marker of vitamin K status) in adult patients with CD currently
in remission as it does in healthy adults and second determine the effect of supplementation with phylloquinone at this dose for 12 months on
the indices of bone turnover and bone mass. The initial dose-ranging RCT was conducted in adult patients with CD (n 10 per group) using 0
(placebo), 1000 or 2000mg of phylloquinone daily for 2 weeks. In the main RCT, the effect of placebo v. 1000mg vitamin K/d (both co-
administered with Ca (500mg/d) and vitamin D3 (10mg/d)) for 12 months (n 43 per group) on the biochemical indices of bone turnover
(determined by enzyme immunoassay) and bone mass (determined by dual-energy X-ray absorptiometry) were investigated. At baseline,
the mean %ucOC was 47%, and this was suppressed upon supplementation with 1000 mg of phylloquinone daily (281%; P,0·01) and
not suppressed further by 2000mg of phylloquinone daily. Compared with the placebo, supplementation with 1000mg of phylloquinone
daily for 12 months had no significant effect (P.0·1) on bone turnover markers or on the bone mass of the lumbar spine or femur, but mod-
estly increased (P,0·05) the bone mass of the total radius. Despite near maximal suppression of serum %ucOC, supplementation with 1000mg
of phylloquinone daily (with Ca and vitamin D3) had no effect on the indices of bone health in adult CD patients with likely vitamin K
insufficiency.
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Osteopaenia and osteoporosis are common conditions among
patients with Crohn’s disease (CD)(1,2). Bone loss resulting
from these conditions is a major risk factor for osteoporotic
fractures of the spine, wrist and hip(3), which can have a
deleterious effect on the quality of life of patients with CD,
especially in young patients who have a normal life
expectancy. Although the pathogenesis of osteopaenia and
osteoporosis in CD is likely to be multifactorial, the existence
of nutritional inadequacies of Ca and vitamin D in these
patients has been implicated(4–9).
The prevalence of vitamin K deficiency in patients with
chronic gastrointestinal disorders has been known for some
time(10). The concentration of undercarboxylated osteocalcin
(ucOC) and the percentage of osteocalcin present in an under-
carboxylated state (%ucOC) are markers of diminished vitamin
K nutritive status(11). Adult patients with CD, even those in
remission and not taking high-dose steroids, have been
shown to have higher circulating ucOC concentrations and/
or %ucOC compared with age- and sex-matched healthy con-
trol subjects(12–14). The increased serum ucOC concentration
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and/or %ucOC in patients with CD in these studies appeared
to be positively associated with the rate of bone turnover(13,14)
and inversely correlated with the bone mineral density (BMD)
of the lumbar spine, but not with that of the femoral neck or
total body(12). In a multiple regression analysis, Kuwabara
et al.(15) showed that in addition to BMI, plasma phyllo-
quinone concentration is a significant determinant of the
BMD of the lumbar spine and distal one-third radius, but
not of that of the total hip and femoral neck in patients with
adult inflammatory bowel disease (IBD). However, in terms
of proof of causality, there is a need for data from double-
blind, randomised controlled trials of phylloquinone
supplementation in patients with CD to confirm these positive
observational findings. This is important in terms of informing
nutrition-based guidelines for the prevention of osteoporosis
in IBD patients, which at present focus only on vitamin D
and Ca(6,16).
If there is a causal relationship between high %ucOC and
higher bone turnover and lower BMD in adult patients with
CD, then suppression of %ucOC by an increased intake of
phylloquinone should lead to bone health benefits in this
‘at-risk’ patient group. In their short-term, dose-related (ran-
ging from 250 to 2000mg/d) phylloquinone supplementation
study, Binkley et al.(17) showed that a supplemental intake
of 1000mg phylloquinone/d was required to near-maximally
suppress %ucOC (i.e. .70 %) in healthy subjects. However,
with possible differences in the efficiency of intestinal absorp-
tion of phylloquinone in adult patients with CD(13), it is not
clear whether 1000mg of phylloquinone daily will maximally
suppress %ucOC in these at-risk patients. The aims of the pre-
sent study were to carry out two double-blind, randomised,
placebo-controlled trials in adult patients with CD currently
in remission to first establish whether phylloquinone sup-
plementation at a dose of 1000mg/d or at a higher dose of
2000mg/d near-maximally suppresses ucOC and %ucOC
in adult patients in CD and second investigate the effect of
supplementation with the required dose of phylloquinone,
in addition to Ca and vitamin D, for 12 months on bone turn-
over and bone mass in patients with CD.
Subjects and methods
Subjects
Patients (aged 18–70 years) visiting the Cork University
Hospital IBD Clinic, Cork, Ireland, who were diagnosed with
CD and were in clinical remission were randomly asked to
participate in the study. There was no selection bias other
than that those selected to participate in the study had to be
in relatively close geographical proximity to the research
centre in consideration of patient inconvenience. CD was pre-
viously diagnosed on the basis of consistent clinical findings,
Ba radiology and histology. Clinical remission was defined
at the time of the study as the absence of gastrointestinal
symptoms and not requiring therapeutic doses of cortico-
steroids. In addition, disease activity was assessed according
to the Harvey–Bradshaw index(18). Of the sixty-eight patients
who completed the main RCT (study B, described below),
two (3 %) had a Harvey–Bradshaw index of 5 (erythrocyte
sedimentation rates of 5 and 17 mm/h, respectively), whereas
the remaining sixty-six (97 %) who participated in study B and
all patients who participated in the short-term dose-ranging
RCT (study A, described below) had inactive disease.
A total of thirty adult patients with CD (eighteen males and
twelve females; mean age 45·4 (SD 12·6) years) participated in
study A (a 2-week phylloquinone intervention trial). Consent-
ing adult Caucasian men and women aged 18–70 years with
long-standing (.5 years of duration) CD in remission at the
time of inclusion were eligible to participate in this trial.
Reasons for exclusion were severe medical illness, hypercal-
caemia, known intestinal malabsorption syndrome, excessive
intake of alcohol, use of medications known to interfere
with vitamin D and/or vitamin K metabolism, pregnancy,
diagnosis of osteoporosis before inclusion in the study, and
use of bisphosphonates or vitamin/mineral supplements. As
regards medication use, fifteen patients with CD were on
maintenance 5-aminosalicylate (400–1200 mg/d) therapy,
eight were taking 6-mercaptopurine (50 mg/d) and one was
taking azathioprine (100 mg/d). Furthermore, two patients
were taking infliximab either monthly or bimonthly. None of
the patients was taking steroids, warfarin or methotrexate
during the study. At the time of inclusion, none of the patients
was taking activated forms of vitamin D (25-hydroxyvitamin D
(25(OH)D) or 1,25-dihydroxyvitamin D) or calcitonin, while
nine patients were regular cigarette smokers. None of the
patients was taking vitamin K supplements during the study.
Among the patients who participated in study A, only 20 %
had small bowel involvement, 20 % had inflammation of the
colon and 60 % had inflammation of both sites. Furthermore,
47 % of the patients had undergone a previous terminal ileal
resection (,50 cm), and none ever had steatorrhoea or short
bowel syndrome.
A total of eighty-six adult patients with CD (forty-eight
males and thirty-eight females; mean age 41·3 (SD 10·2)
years) participated in study B (a 12-month phylloquinone
intervention trial). Of these, twenty patients had participated
in study A. Inclusion criteria and reasons for exclusion
were the same as those of study A, with one additional
reason for exclusion, i.e. planning to become pregnant
during the 12-month intervention trial. As regards medication
use, twenty-nine patients with CD were on maintenance
5-aminosalicylate (500–3000 mg/d) therapy, thirty-one were
taking 6-mercaptopurine (50–75 mg/d) and four were taking
azathioprine (50–100 mg/d). Furthermore, three were taking
sulfasalazine (1–2 g/d) and eleven were taking adalimumab
(40 mg) either weekly or bimonthly, while five were taking
infliximab every 4–6 weeks. None of the patients was taking
steroids, warfarin or methotrexate at the time of inclusion or
was taking warfarin during the study. At the time of inclusion,
none of the patients was taking activated forms of vitamin D
(25(OH)D or 1,25-dihydroxyvitamin D) or calcitonin, while
twenty-one patients were regular cigarette smokers. None of
the patients was taking vitamin K supplements during the
study. Among those who participated in study B, only 31 %
had small bowel involvement, 25 % had inflammation of the
colon and 44 % had inflammation of both sites. Furthermore,
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47 % of the patients had a previous terminal ileal resection
(,50 cm), and none ever had steatorrhoea or short bowel
syndrome.
During the 12-month intervention trial (study B), thirteen
(19 %) of the sixty-eight patients experienced a CD-related dis-
ease flare-up: seven were randomised to the placebo group
and six were randomised to the phylloquinone treatment
group. Of those who experienced a CD-related flare-up,
eleven (85 %) reported only one flare-up, while two (15 %)
reported more than one flare-up (two and four, respectively)
during the intervention period. A range of medical interven-
tions were used to treat flare-ups, including metronidazole
(10 mg/kg), oral prednisolone (tapering weekly from 40 mg/
d), budesonide (range 3–9 mg/d) and/or prednisolone foam
enema (once to twice daily).
Ethical considerations
The present study was conducted according to the guidelines
laid down in the Declaration of Helsinki, and all procedures
involving patients were approved by the Clinical Research
Ethics Committee of the Cork Teaching Hospitals, Cork,
Ireland (October, 2006). Written informed consent was
obtained from all patients. The study was also registered at
ClinicalTrails.gov (http://clinicaltrials.gov/show/NCT01235325
(ClinicalTrials.gov identifier: NCT01235325)).
Design and conduct of studies
Study A was a short-term, double-blind, placebo-controlled
trial in which patients with CD (n 10 per group) were
randomly assigned to receive 0 (placebo), 1000 or 2000mg
of supplemental phylloquinone daily for 2 weeks. The study
was conducted between January and December 2007. The
participants took two capsules (each containing 0 or 1000mg
of phylloquinone) daily so as to receive the three assigned
doses in addition to their habitual dietary phylloquinone
intake amounts. Because phylloquinone is fat soluble, the
participants were instructed to take the capsules with their
evening meal so as to maximise absorption. Phylloquinone
(1000mg) capsules and matching placebo capsules were
produced by Banner Pharmacaps and were identical in
appearance and taste. Randomisation was computer-generated
and stratified for sex. The phylloquinone content of the
capsules was independently confirmed by HPLC analysis.
Compliance was assessed by capsule counting. The allocation
remained concealed until the final analyses, and all data were
reported by individuals who were blinded to the allocation
scheme.
All participants were given supplemental vitamin D3
(10mg/d) and Ca (500 mg/d) (as Calcichew D3 Forte
chewable tablets, kindly supplied by Shire Pharmaceuticals
Ireland Limited) for 2 weeks before the phylloquinone inter-
vention trial and throughout the trial, so as to correct any
potential serious deficiencies of these nutrients. Each
participant attended a screening session at the IBD Clinic
during which a blood sample was collected for basic clinical
haematology and biochemistry profiles, and anthropometric
measurements were taken. Habitual intakes of Ca, vitamin D
and phylloquinone were assessed using a FFQ specifically
developed for Irish adults(19), which was administered by
a research nutritionist. During the screening session, the par-
ticipants were given the supplemental vitamin D3 (10mg/d)
and Ca (500 mg/d) tablets and were asked to commence
taking them daily. After 2 weeks, each participant returned
to the IBD Clinic to provide an overnight fasting blood
sample (20 ml; taken between 08.30 and 10.30 hours by a
trained phlebotomist) on day 0 (pre-intervention) and
again on day 14 (post-intervention). Blood was collected by
venepuncture into an evacuated tube without an additive
and processed to serum, which was immediately stored at
2808C until analysis.
Study B was a 12-month, double-blind, placebo-controlled
trial (conducted between July 2009 and December 2010) in
which patients with CD (n 43 patients per group) were
randomly assigned to receive the placebo or 1000mg of sup-
plemental phylloquinone daily for 12 months in addition
to their habitual dietary phylloquinone intake amounts. The
supplemental dose of phylloquinone was chosen on the
basis that it was found to be sufficient to near-maximally
suppress the degree of under-g-carboxylation of serum osteo-
calcin in study A (see the Results section). As in study A, the
participants were instructed to take the capsules with their
evening meal so as to maximise absorption, and all partici-
pants were given supplemental vitamin D3 (10mg/d) and Ca
(500 mg/d) (Calcichew D3 Forte chewable tablets; Shire
Pharmaceuticals Ireland Limited) throughout the intervention
period, so as to correct any potentially serious deficiencies
of these nutrients. Randomisation was computer-generated
and stratified for sex. Compliance was assessed by capsule
counting. An a priori decision was made to include only
those participants with .80 % compliance in compliance-
based analysis to extend the intention-to-treat analysis. The
allocation remained concealed until the final analyses, and
all outcomes were reported by individuals who were blinded
to the allocation scheme.
Each participant made a baseline visit to the IBD Clinic during
which a blood sample was collected for basic clinical haematol-
ogy and biochemistry profiles as well as vitamin and bone bio-
marker status assessment, and anthropometric measurements
were taken. Habitual intakes of Ca, vitamin D and phylloqui-
none were assessed using a FFQ as in study A. After 6 and 12
months, each participant returned to the IBD Clinic to provide
an overnight fasting blood sample (20 ml; taken between
08.30 and 10.30 hours by a trained phlebotomist). Blood was
collected by venepuncture into an evacuated tube without an
additive and processed to serum, which was immediately
stored at 2808C until analysis. In addition, a fasting urine
sample was collected, which was immediately stored at 2208C
until analysis. Serum osteocalcin markers of vitamin K status
and basic clinical haematology and biochemistry profiles were
assessed at baseline, midpoint and endpoint. BMD and bone
mineral content (BMC) as well as serum- and urine-based
markers of bone turnover and serumphylloquinone (subsample
only) were assessed at baseline and at endpoint.
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B
ri
ti
sh
Jo
u
rn
al
o
f
N
u
tr
it
io
n
https://www.cambridge.org/core/terms. https://doi.org/10.1017/S0007114514001913
Downloaded from https://www.cambridge.org/core. Mary Immaculate College of Education, on 07 Apr 2018 at 13:25:30, subject to the Cambridge Core terms of use, available at
Bone densitometry
BMD and BMC were measured by dual-energy X-ray absorp-
tiometry (GE iDXA Lunar Phantom) at the lumbar spine
(L2–L4), femur (total hip, neck, Ward’s triangle and trochan-
ter) and non-dominant radius (total, ultradistal and distal
one-third). All tests were carried out according to a standard
protocol on the same machine (using enCore software version
13.4) and by the same trained technician at the Cork Univer-
sity Hospital. The prevalence of osteopaenia and confirmation
of the absence of osteoporosis were assessed according to the
WHO classification in which osteopaenia is defined as a
T score ranging between 21 and 22·5 and osteoporosis as
a T score less than 22·5 (normal: T score greater than 21)(20).
Laboratory analysis
Serum 25-hydroxyvitamin D. The concentration of serum
25(OH)D was measured using an ELISA (OCTEIAw 25-
Hydroxy Vitamin D; Immunodiagnostic Systems Limited).
The intra-assay CV was 5·9 %. The quality and accuracy of
serum 25(OH)D analysis carried out in the present study
was ensured on an ongoing basis by participation in the
Vitamin D External Quality Assessment Scheme (Charing
Cross Hospital, London, UK).
Serum intact parathyroid hormone. The concentration of
serum intact parathyroid hormone (PTH) was measured
using an ELISA (OCTEIAw Intact Parathyroid Hormone; Immu-
nodiagnostic Systems Limited). The intra-assay CV was 3·4 %.
Serum carboxylated and undercarboxylated osteocalcin.
The concentrations of serum carboxylated osteocalcin (cOC)
and ucOC were measured using ELISA (Gla and Glu EIA Kits;
Takara Biomedical Group). The intra-assay CV for ucOC and
cOC were 4·4 and 4·5 %, respectively. The %ucOC was
calculated by expressing serum ucOC as a percentage of total
osteocalcin values (serum ucOC þ serum cOC). Although a
threshold of serum %ucOC defining vitamin K insufficiency
has not been established yet, we have previously shown that
adult patients with CD in remission had a significantly higher
mean %ucOC compared with age- and sex-matched healthy
control subjects (47·6 v. 37·0 %, respectively(13)).
Serum phylloquinone. The concentration of serum phyllo-
quinone was measured by reversed-phase HPLC with
fluorescence detection using the method described by Wang
et al.(21). An internal standard compound (a proprietary vitamin
K derivative) (Immundiagnostik AG) was also used in this
analysis. The intra-assay CV was ,6%. While serum phyllo-
quinone concentration was determined in all patients who
participated in study A, it was measured in only a subset of
patients (twenty-seven of the sixty-eight) who participated in
study B due to resource limitations. Unfortunately, a reference
range for serum phylloquinone concentrations in the healthy
adult population, aged 18–70 years, in Ireland is not currently
available. For the purposes of the present study, we defined a
serum phylloquinone concentration,0·4 nmol/l as ‘low’ on the
basis of reference ranges in healthy adults, which has been
previously cited as a cut-off value in clinical studies carried
out in the USA(22) and the UK(23).
Serum bone-specific alkaline phosphatase. The activity of
serum bone-specific alkaline phosphatase (BAP) was
measured using an ELISA (Metrae Osteocalcin EIA Kit;
Quidel Corporation). The intra-assay CV was 5·0 %.
Serum C-terminal telopeptide of type I collagen. The con-
centration of serum C-terminal telopeptide of type I collagen
(CTx) was measured using the Serum CrossLapsw ELISA
Kit (Nordic Bioscience Diagnostics A/S). The intra-assay CV
was 5·0 %.
Urinary N-telopeptides of type I collagen. The concentra-
tions of urinary N-telopeptides of type I collagen (NTx) were
measured using the Osteomark ELISA Kit (Unipath Limited).
The concentration of urinary creatinine was measured using
a quantitative, colorimetric assay from Metra (Quidel Corpor-
ation). The intra-assay CV for NTx and creatinine were 8·3
and 3·4 %, respectively. The concentration of urinary NTx is
expressed relative to that of urinary creatinine.
Inter-assay variability in the above-mentioned variables was
avoided by analysing all samples collected from an individual
in the same run.
Statistical analysis
In their short-term, dose-related phylloquinone supplemen-
tation study in healthy young adult and older subjects, Binkley
et al.(17) showed that a supplemental intake of 1000mg
phylloquinone/d is required to near-maximally suppress
%ucOC (approximately 74 % reduction). With possible
differences in the efficiency of intestinal absorption of phyllo-
quinone in adult patients with CD(13), it was not clear whether
this supplemental dose of phylloquinone would near-
maximally suppress %ucOC in patients with CD (this was
the main objective of study A). On the basis of the distribution
of serum ucOC and %ucOC data collected from adult patients
with CD from our previous study(13), a study design recruiting
ten volunteers per group was found to have 90 % power to
detect a $70 % reduction in serum ucOC concentration and
%ucOC between the groups at a ¼ 0·5. As the study was
very acute, we assumed no dropout. On confirmation of the
ability of 1000mg of phylloquinone to induce near-maximal
suppression of serum ucOC concentration and %ucOC in
patients with CD in study A, we aimed to determine the
effect of this dose of phylloquinone on the markers of bone
turnover and bone mass in adult patients with CD after
12 months of supplementation. Using the standardised coeffi-
cients from our previous multiple regression analysis of the
association between serum ucOC and urinary NTx concen-
trations in adult patients with CD(13), we expected a 38 %
reduction in urinary NTx concentrations arising from the
anticipated decrease in serum ucOC concentrations following
supplementation with 1000mg of phylloquinone daily
(as observed in study A) for 12 months. On the basis of the
distribution of urinary NTx data collected from adult patients
with CD from our previous study(13), a study design (study
B) recruiting thirty-two volunteers per group was found to
have 90 % power to detect a reduction of 35 % in urinary
NTx concentrations arising from a $70 % reduction in serum
ucOC concentrations between vitamin K-supplemented and
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unsupplemented groups at a ¼ 0·5. We assumed a dropout
rate #25 % over the 12-month trial and thus recruited forty-
three volunteers per group.
Statistical analysis of the data was conducted using SPSS for
Windows software (version 18.0; SPSS, Inc.) and DataDesk
for Mac OS software (version 6.0; Data Description, Inc.).
Descriptive statistics (means and standard deviations, medians
and interquartile ranges (IQR), where appropriate) were
determined for all variables. The distributions of all variables
were tested using the Kolmogorov–Smirnov test. In study A,
serum ucOC, cOC, %ucOC and phylloquinone values as
well as dietary Ca intake values were not normally distributed
and thus were log-transformed to achieve near-normal distri-
butions. Similarly in study B, serum phylloquinone, PTH,
BAP and CTx and urinary NTx/creatinine values as well as
dietary Ca, vitamin D and phylloquinone intake values were
not normally distributed and thus were log-transformed to
achieve near-normal distributions. The baseline characteristics
of subjects in the different intervention groups in the two
studies were compared separately using the x 2 test (for the
male:female ratio and smoker:non-smoker ratio) and unpaired
Student’s t test (study B) or one-factor ANOVA (study A). In
study A, differences in the markers of vitamin D and K
status at baseline and endpoint were assessed using one-
factor ANOVA followed by Tukey’s post hoc tests. In study
B, linear models of the response in a repeated-measures
analysis for differences in the markers of K status were con-
structed. The main effects included were dietary treatment
(placebo or 1000mg phylloquinone) and sex. The linear
models also included two-way interactions between the
main effects. Differences in serum PTH and 25(OH)D concen-
trations as well as bone measures within a group from
baseline to endpoint were assessed using paired Student’s
t tests with Bonferroni adjustment, while differences in these
indices between the placebo and phylloquinone treatment
groups at baseline were compared using unpaired Student’s
t tests with Bonferroni adjustment. Regression models were
run to adjust the BMD and BMC data for possible confounding
effects of sex, age, BMI, baseline serum 25(OH)D concentration,
smoking status, alcohol consumption, bowel involvement,
resection, disease duration, daily Ca intake, infliximab and
adalimumab use, disease flare-up during the 12-month inter-
vention period, and medication use for disease flare-up.
A P value,0·05 was considered to be statistically significant.
Results
Baseline characteristics of subjects in study A
All subjects recruited to study A completed the trial. The mean
age, weight, height, BMI, duration of CD, and habitual intakes
of Ca, vitamin D and phylloquinone as well as the male:female
ratio of these subjects are given in Table 1. There were no sig-
nificant differences (P.0·1) in mean age, weight, height, BMI,
duration of CD, or mean habitual intakes of Ca, vitamin D and
phylloquinone among the three intervention groups (data not
shown). Similarly, there was no significant difference (P¼0·4)
in the male:female ratio among the three intervention groups
(data not shown). The median serum phylloquinone concen-
tration was 0·64 (IQR 0·50–1·54) nmol/l.
Effect of phylloquinone intervention on the markers of
vitamin K and D status in study A
There were no significant differences in any of the bio-
chemical indices of vitamin D and K status among the three
intervention groups at baseline (Table 2). There was good
supplement adherence, as determined by capsule counting
(median 100 (IQR 96–100) %), and compliance did not differ
significantly (P¼0·8) among the three intervention groups.
There was a significant (P,0·0001–0·002) effect of phyllo-
quinone intervention on mean serum phylloquinone, ucOC
and cOC concentrations as well as on serum %ucOC
(Table 2). Compared with those in patients who were given the
placebo, serum phylloquinone concentrations were significantly
(P,0·0001) increased in a dose-responsive manner in patients
who were given 1000 or 2000mg of phylloquinone daily for
2 weeks (Table 2). Serum cOC and ucOC concentrations were
significantly (P,0·01) higher and lower, respectively, in patients
who were given 1000 or 2000mg of phylloquinone daily for
2 weeks than in those who were given the placebo, with no
significant difference being observed between the two
phylloquinone treatment groups (Table 2). Compared with that
in patients who were given the placebo, serum %ucOC was
significantly (P,0·01) reduced in patients who were given
1000mg (281·0%) or 2000mg (289·5%) of phylloquinone
daily for 2 weeks, with no significant difference being observed
between the two phylloquinone treatment groups (Table 2).
Baseline characteristics of subjects in study B
Of the eighty-six subjects recruited to study B, seventy-seven
returned for the 6-month assessment session, and sixty-eight
completed the intervention phase. The progress of these
subjects through the trial is shown in Fig. 1. The male:female
ratio and mean age, weight, height, BMI, duration of CD, and
Table 1. Baseline characteristics of adult patients with long-standing
Crohn’s disease (CD) in remission who completed the dose-ranging
intervention trial (study A)
(Mean values and standard deviations; medians and interquartile ranges
(IQR) in the case of non-normally distributed parameters)
Mean SD
Final (n) 30
At recruitment (n) 30
Males (n) 18
Females (n) 12
Age (years) 45·5 12·6
Height (m) 1·69 0·10
Weight (kg) 80·9 16·6
BMI (kg/m2) 28·3 5·2
Duration of CD (years) 15·4 8·8
Dietary Ca intake (mg/d)
Median 1272
IQR 1038–1743
Dietary vitamin D intake (mg/d) 5·4 2·9
Dietary phylloquinone intake (mg/d) 120 57
Phylloquinone and bone health in Crohn’s disease 1167
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habitual intakes of Ca, vitamin D and phylloquinone of
patients completing the trial, as an entire group and stratified
by the treatment group, are given in Table 3. There were no
significant differences in any of the baseline characteristics
(P.0·2). The median serum phylloquinone concentration in
a subset of patients (n 27) was 0·43 (IQR 0·25–1·16) nmol/l,
and twelve of the twenty-seven patients (44 %) had serum
concentrations ,0·4 nmol/l(22,23). There were no significant
differences in any of the biochemical indices of vitamin K
status (Fig. 2) or markers of bone turnover or serum PTH
(Table 4) between the two groups at baseline. Serum
25(OH)D concentrations were significantly (P,0·05) lower
(by 9 nmol/l, on average) in the placebo group than in the
phylloquinone treatment group at baseline (Table 3).
Prior diagnosis of osteoporosis on study entry was an exclu-
sion criterion, and its absence in all patients was confirmed by
baseline DXA scan. In this study, five patients (7%) (three in the
placebo group and two in the phylloquinone treatment group)
had osteopaenia; the remainder had normal BMD values at
baseline. There were no significant differences in unadjusted
BMD or BMC at any of the skeletal sites between the two
groups at baseline, with the exception of a significantly
(P,0·05) higher BMD of the 33% radius in the phylloquinone
treatment group than in the placebo group (Table 5).
Compliance and effect of phylloquinone intervention on
the markers of vitamin K status in study B
No serious adverse events were reported during study B. A
total of four participants reported adverse events due to the
co-administration of the Ca/vitamin D supplement with
phylloquinone or the placebo, which ranged from cramps
and diarrhoea to occasional pain in legs and fingers. Of the
eighteen dropouts, eleven and seven were from the placebo
and 1000mg phylloquinone/d groups, respectively. The
participants dropped out for a variety of reasons (such as
pregnancy, loss of interest, personal reasons, relocation, and
illness unrelated to the intervention), and in no instance was
dropout related to the intervention. In this study, eight
subjects (four in each group) failed to exceed the minimum
compliance level of 80 % set, and these were excluded
from the main analysis in the compliance-based approach to
extend the intention-to-treat analysis. Good supplement
Table 2. Biochemical measures of vitamin D and K status among the treatment groups before and after the 2-week intervention trial
(study A) in adult patients with long-standing Crohn’s disease in remission
(Mean values and standard deviations; medians and interquartile ranges (IQR) in the case of non-normally distributed parameters)
Treatment groups. . .
Placebo (n 10)
1000mg phylloquinone/d
(n 10)
2000mg phylloquinone/d
(n 10)
Median IQR Median IQR Median IQR P*
Serum 25(OH)D (nmol/l)
Pre-intervention 0·435
Mean 81·8 66·9 76·4
SD 25·9 19·6 30·9
Post-intervention 0·492
Mean 85·2 70·0 80·2
SD 32·6 20·1 31·3
Serum ucOC (ng/ml)
Pre-intervention 4·4 3·2–9·5 5·0 3·2–10·0 3·2 1·3–4·6 0·212
Post-intervention 4·5a 2·8–9·5 1·1b 0·7–2·1 0·7b 0·1–1·0 ,0·0001
Serum cOC (ng/ml)
Pre-intervention 4·6 3·4–8·9 6·9 3·5–10·7 3·1 2·3–4·4 0·630
Post-intervention 3·8a 2·7–7·5 16·3b 13·8–22·4 9·7b 8·3–15·1 0·002
Serum %ucOC
Pre-intervention 48·5 34·4–71·3 41·0 23·1–65·9 46·5 36·1–56·3 0·741
Post-intervention 56·7a 27·2–76·6 7·8b 6·2–11·8 4·9b 0·6–6·2 ,0·0001
Serum phylloquinone (nmol/l)
Pre-intervention 0·62 0·49–0·95 0·67 0·52–0·87 0·88 0·40–2·50 0·525
Post-intervention 0·63a 0·54–1·05 3·42b 2·58–9·24 16·4c 8·55–25·5 ,0·0001
25(OH)D, 25-hydroxyvitamin D; ucOC, undercarboxylated osteocalcin; cOC, carboxylated osteocalcin; %ucOC, percentage of undercarboxylated osteocalcin.
a,b,c Median values with unlike superscript letters were significantly different among the treatment groups (P,0·001; Tukey’s post hoc tests).
* One-way ANOVA.
Eighty-six randomised
Forty-three placebo
Forty-three
(1000 µg/d)
phylloquinone
Forty midpoint
Dropouts = 3
Thirty-seven midpoint
Dropouts = 6
Thirty-six endpoint
Dropouts = 4
(non-compliers = 4)
Thirty-two endpoint
Dropouts = 5
(non-compliers = 4)
Month 0
Month 6
Month 12
Fig. 1. Progress of the participants of study B through the trial.
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adherence, as determined by capsule counting, was observed
in the remaining subjects (overall median compliance: 93 (IQR
89–97) % and compliance was similar between the two
groups; P.0·7).
Using a compliance-based approach, it was found that there
were no significant differences at baseline in mean age,
weight, height, BMI and duration of CD, male:female ratio,
habitual intakes of Ca, vitamin D and phylloquinone, and
any of the biochemical indices of vitamin K status or markers
of bone turnover between the two groups (data not shown).
Serum 25(OH)D concentrations tended (P¼0·059) to be
lower in the placebo group (n 28) than in the phylloquinone
treatment group (n 32) at baseline (median 40·9 (IQR
32·6–54·6) v. 53·4 (IQR 40·0–74·5) nmol/l, respectively).
There were no significant differences in unadjusted BMD or
BMC at any of the skeletal sites between the two groups
at baseline (data not shown), with the exception of a
significantly (P,0·05) higher BMD of the 33 % radius in the
phylloquinone treatment group than in the placebo group
(median 0·757 (IQR 0·712–0·816) v. 0·670 (IQR 0·620–0·806)
g/cm2, respectively).
Irrespective of using the compliance-based or intention-
to-treat approach, a significant (P,0·001) ‘time £ treatment’
interaction effect (in a repeated-measures ANOVA model)
was observed on serum ucOC and cOC concentrations as
well as on serum %ucOC over the 12-month intervention
period (Fig. 2). Compared with those at baseline, mean
serum cOC and ucOC concentrations at endpoint were signifi-
cantly higher (76 %; P,0·001) and lower (280 %; P,0·001),
respectively, in patients who were given 1000mg of phylloqui-
none daily, whereas there were no significant changes from
baseline values in those who were given the placebo (Fig. 2).
Compared with that at baseline, mean serum %ucOC at end-
point was significantly reduced (282 %; P,0·001) in patients
who were given 1000mg of phylloquinone daily, whereas
there were no significant changes from baseline values in
those who were given the placebo (Fig. 2). The response of
serum ucOC, cOC and %ucOC at 12 months was evident
in the phylloquinone treatment group and was of a similar
magnitude at 6 months (Fig. 2). The median (IQR) serum
phylloquinone concentration was significantly increased by
Table 3. Baseline characteristics of adult patients with long-standing Crohn’s disease (CD) in remission who completed the 12-month
intervention trail (study B)
(Mean values and standard deviations; medians and interquartile ranges (IQR) in the case of non-normally distributed parameters)
Entire sample Placebo group Phylloquinone group
Median IQR Median IQR Median IQR P*
Final (n) 68 32 36
At recruitment (n) 86 43 43
n 0·330
Males 37 15 22
Females 31 17 14
Age (years) 0·598
Mean 41·3 40·7 42·0
SD 10·2 10·5 10·0
Height (m) 0·277
Mean 1·69 1·68 1·70
SD 0·09 0·09 0·09
Weight (kg) 0·306
Mean 75·2 73·0 77·1
SD 16·7 17·6 15·8
BMI (kg/m2) 26·2 22·5–29·1 25·0 22·0–28·0 26·5 23·0–30·0 0·454
Duration of CD (years) 0·557
Mean 14·0 14·5 13·5
SD 7·1 8·4 5·8
Dietary Ca intake (mg/d) 1337 863–1796 1421 860–1790 1220 887–1895 0·572
Dietary vitamin D intake (mg/d) 4·6 3·0–7·4 5·2 3·3–7·4 4·5 2·8–7·3 0·833
Dietary phylloquinone intake (mg/d) 95·7 58·3–142·3 91·2 55·2–145·4 98·7 60·0–138·0 0·870
* Placebo group v. phylloquinone group (determined by the x 2 or unpaired Student’s t test).
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Fig. 2. Serum carboxylated osteocalcin (cOC (ng/ml), ) and undercarboxy-
lated osteocalcin (ucOC (ng/ml), ) concentrations and percentage of ucOC
(%ucOC, ) among adult patients with Crohn’s disease before and after the
12-month intervention trial (study B; (a) phylloquinone; (b) placebo). There was
a significant ‘time £ treatment’ interaction in the repeated-measures ANOVA
(P,0·001): phylloquinone intervention had a significant effect (all P,0·001) on
serum ucOC, cOC and %ucOC values by 6 months, which was of a similar
magnitude at 12 months (a), while there were no significant (P.0·1) changes
from baseline values in those who were given the placebo (a).
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phylloquinone supplementation and remained unchanged in
the placebo group (Table 4).
Effect of phylloquinone intervention on the markers of
bone turnover in study B
Using an intention-to-treat approach, it was found that the
mean serum 25(OH)D concentration increased significantly
(P,0·0001) or tended to increase (P¼0·072) in the placebo
and phylloquinone treatment groups, respectively (Table 3).
Mean serum PTH concentrations decreased significantly
(P,0·01) or tended to decrease (P¼0·079) in the phylloqui-
none treatment and placebo groups, respectively (Table 3).
Serum CTx concentrations decreased significantly (P,0·05)
in both groups (Table 3). There was no significant change in
serum BAP or urinary NTx concentrations in either group
(Table 3).
On using a compliance-based approach, the same trends as
in the intention-to-treat analysis were evident in relation to
serum PTH, CTx, BAP and urinary NTx concentrations.
Table 5. Unadjusted bone mineral density (BMD) and bone mineral content (BMC) values of patients with Crohn’s disease
(n 68) before and after the 12-month intervention trial (study B)
(Mean values and standard deviations)
Placebo group (n 32) Phylloquinone group (n 36)
Baseline 12 months Baseline 12 months
Skeletal site Mean SD Mean SD Mean SD Mean SD
Spine
L2–L4 BMD (g/cm2) 1·194 0·106 1·209 0·127 1·221 0·125 1·217 0·120
L2–L4 BMC (g) 53·538 10·959 55·112 11·311 57·813 9·622 57·456 9·239
Femur
Total BMD (g/cm2) 0·989 0·123 1·006 0·137 1·027 0·170 1·017 0·156
Total BMC (g) 33·407 6·645 34·148 7·124 35·227 6·784 35·324 6·480
Neck BMD (g/cm2) 0·974 0·121 0·984 0·132 0·992 0·181 0·973 0·160
Neck BMC (g) 5·004 0·899 5·073 0·951 5·212 0·984 5·176 0·947
Ward’s BMD (g/cm2) 0·818 0·139 0·825 0·136 0·832 0·207 0·810 0·173
Ward’s BMC (g) 2·418 0·688 2·460 0·697 2·578 0·767 2·581 0·763
Trochanter BMD (g/cm2) 0·783 0·124 0·805 0·139 0·832 0·159 0·833 0·146
Trochanter BMC (g) 10·898 3·070 11·369 3·387 11·748 3·348 11·957 3·145
Radius
Total BMD (g/cm2) 0·540 0·084 0·549 0·085 0·567 0·063 0·572† 0·099
Total BMC (g) 8·609 2·424 9·001 2·478 9·405 2·113 9·610 2·102
33 % BMD (g/cm2) 0·705 0·110 0·725 0·099 0·751* 0·071 0·752 0·072
33 % BMC (g) 1·930 0·450 1·969 0·451 2·091 0·389 2·074 0·399
Ultradistal BMD (g/cm2) 0·378 0·095 0·372 0·012 0·386 0·062 0·389 0·060
Ultradistal BMC (g) 1·493 0·373 1·527† 0·386 1·587 0·345 1·599 0·338
L2–L4, lumbar spine.
* Mean value was significantly different from that of the placebo group at baseline (P,0·05; Bonferroni-adjusted t test).
† Mean value was significantly different from the baseline value within a group (P,0·05; Bonferroni-adjusted t tests).
Table 4. Biochemical measures of vitamin D status and bone turnover among adult patients with Crohn’s disease before and after the 12-month trial
(study B)
(Mean values and standard deviations; medians and interquartile ranges (IQR) in the case of non-normally distributed parameters)
Placebo group (n 32) Phylloquinone group (n 36)
Baseline 12 months Baseline 12 months
Biochemical indices Median IQR Median IQR Median IQR Median IQR
Serum phylloquinone (nmol/l)‡ 0·43 0·25–1·30 0·54 0·22–0·91 0·46 0·26–1·13 7·57††† 3·23–11·11
Serum 25(OH)D (nmol/l)
Mean 48·0 59·0†† 57·0* 65·3
SD 25·4 27·2 22·0 24·0
Serum PTH (pg/ml) 40·0 32·0–59·4 38·5 30·0–50·0 41·5 28·2–55·0 31·0† 21·5–41·3
Serum BAP (U/l) 25·4 20·1–33·5 22·5 18·5–32·0 27·0 19·0–36·0 26·1 20·0–31·3
Serum CTx (ng/ml) 0·45 0·31–0·67 0·44†† 0·29–0·61 0·45 0·3–0·52 0·39†† 0·25–0·49
Urinary NTx/Cr (nmol BCE/nmol) 39·0 29·0–47·3 29·2 25·0–44·0 34·2 25·5–44·0 34·0 28·5–39·0
25(OH)D, 25-hydroxyvitamin D; PTH, parathyroid hormone; BAP, bone alkaline phosphatase; CTx, carboxy-terminal cross-linked telopeptide of type 1 collagen; NTx, cross-
linked N-telopeptides of type I collagen; Cr, creatinine; BCE, bone collagen equivalents.
* Mean value was significantly different from that of the placebo group at baseline (P,0·05; Bonferroni-adjusted t test).
Value was significantly different from the baseline value within a group: †P,0·05; ††P,0·01; †††P,0·0001 (Bonferroni-adjusted t test).
‡ Analysis performed on a subset of patients: n 11 for the placebo group and n 18 for the phylloquinone group.
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The mean serum 25(OH)D concentration increased signifi-
cantly (P#0·02) in both the placebo and phylloquinone
treatment groups (data not shown).
Effect of phylloquinone intervention on bone mineral
density and bone mineral content in study B
Using an intention-to-treat approach, it was found that there
was no significant change (P.0·7) in the weight or BMI of
the participants over the 12-month intervention period in
either the placebo or phylloquinone treatment group (data
not shown). There was no significant effect of phylloquinone
intervention on unadjusted BMD or BMC at any of the spine or
hip skeletal sites (Table 4). The BMD of the total radius, but
not of the ultradistal or 33 % radius, increased significantly
(P,0·05) over the 12-month intervention period in the phyllo-
quinone treatment group (Table 4).
Using a compliance-based approach, it was found that phyl-
loquinone intervention had no effect on unadjusted BMD or
BMC at any of the spine, hip and radius skeletal sites (data
not shown). Furthermore, there was no significant increase
(P.0·1) in the BMD of the total radius over the 12-months
intervention period in the phylloquinone treatment group
(data not shown).
Multiple regression models were run to adjust the BMD and
BMC data for possible confounding effects of sex, age, BMI,
baseline serum 25(OH)D concentration, smoking status,
alcohol consumption, bowel involvement, resection, disease
duration, daily Ca intake, infliximab and adalimumab use,
disease flare-up during the 12-month intervention period,
and medication use for disease fare-up, but the data trends
remained the same (data not shown).
Discussion
In the present study carried out in adult patients with long-
standing CD, in clinical remission on study entry and with
adequate intakes of vitamin D and Ca, supplementation with
1000mg of phylloquinone for 12 months had no significant
effect on the indices of bone turnover and bone mass, with
the possible exception of a modest beneficial effect on total
forearm BMD. These findings were recorded despite the fact
that the patients had, on average, a relatively high proportion
of their serum osteocalcin in an under-g-carboxylated state
(approximately 48 %) and 44 % had a serum phylloquinone
concentration ,0·4 nmol/l, indicating the presence of
vitamin K insufficiency in this at-risk group, who upon supple-
mentation with phylloquinone exhibited a near-maximised
g-carboxylation status of serum osteocalcin.
It is unclear whether the lower vitamin K status in patients
with CD is associated with insufficient dietary intake or with
some degree of malabsorption of the vitamin, or indeed
both. The group of patients with CD who participated in the
12-month intervention trial had a median habitual daily
intake of phylloquinone of 95·7mg vitamin K1/d, with 39 %
having intake values below the European Union and UK
recommendation of 1mg vitamin K1/kg body weight per
d(24,25) and 60 % with intake values below the North American
sex-specific adequate intake values for vitamin K(26). Whatever
be the exact underlying reasons for the lower vitamin K status
among the patients with CD, it was not surprising to find sig-
nificant and rapid changes in the indices of vitamin K status
upon supplementation with phylloquinone, even after
2 weeks (study A), which were of a magnitude similar to
that observed after 6 and 12 months of intervention (study
B). For example, the median serum phylloquinone concen-
tration increased by about 11-fold in patients with CD who
were supplemented daily with 1000mg of phylloquinone for
12 months. In their 2-year trial in postmenopausal women,
Bolton-Smith et al.(27) showed that the mean serum phyllo-
quinone concentration increased by about 2-fold with
200mg/d phylloquinone supplementation. Serum ucOC and
cOC concentrations were significantly reduced and increased,
respectively, and consequently serum %ucOC was dramati-
cally reduced (.80 %, on average), in the patients with CD
on supplementation with 1000mg of phylloquinone daily for
2 weeks, with no further significant changes being observed
in these indices in the 2000mg phylloquinone/d group.
These findings in patients are in line with those reported
by Binkley et al.(17), who in their short-term, dose-related
phylloquinone supplementation study (in the range of
250–2000mg/d) in healthy young adult and older subjects
found that a supplemental intake of 1000mg phylloquinone/
d was required to near-maximally suppress %ucOC and thus
optimise bone vitamin K status. While in the study carried
out by Binkley et al.(17) phylloquinone was provided alone,
in the present study, it was provided together with Ca and
vitamin D, so as to ensure adequacy in all patients. In their
2-year trial in postmenopausal women, Bolton-Smith et al.(27)
showed that %ucOC reduced from approximately 50 % to
approximately 25 % with the more likely dietary attainable
supplemental dose of phylloquinone (200mg/d) and, impor-
tantly, the response was similar whether phylloquinone was
given alone or with Ca and vitamin D. The suppression of
serum %ucOC in patients with CD in the present study
achieved after supplementation with 1000mg of phylloqui-
none daily for 2 weeks proved to be of a magnitude similar
to that achieved after 6 and 12 months in our year-long trial.
The circulating concentration of ucOC (or %ucOC) has been
reported to be a predictor of hip fracture risk in healthy indi-
viduals(28,29). Moreover, in observational studies of adult
patients with CD, increased serum ucOC concentration and
%ucOC have been shown to be positively associated with
the rate of bone turnover(13,14) and inversely correlated with
the BMD of the lumbar spine(12,30). However, in the present
study, despite the near-maximal suppression of %ucOC by
supplementation with phylloquinone for 12 months, no sig-
nificant effects were observed on urinary NTx concentrations
and other biochemical markers of bone turnover or on the
BMC and BMD of the spine or femur in adult patients with
CD who had adequate intakes of vitamin D and Ca, but prob-
ably had vitamin K insufficiency. Intention-to-treat (but not
compliance-based) analysis showed that the BMD of the
total radius increased modestly, but significantly, in patients
supplemented with 1000mg of phylloquinone daily together
with Ca and vitamin D for 12 months.
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The decision to determine the effect of increased phyllo-
quinone intake, and thus greatly enhanced vitamin K status,
on bone health while ensuring nutritional adequacy of Ca
and vitamin D intakes in the patients with CD was made
with the following in mind: dietary reference intake values
for any one nutrient (e.g. phylloquinone) presuppose that
requirements for energy and all other nutrients (such as Ca
and vitamin D) are met; the available data from RCT in healthy
adults or adults with osteopaenia seem to suggest that in those
studies where a beneficial effect with phylloquinone on bone
was evident(27,31,32), and some studies reported no ben-
efit(32,33,34), it was, in general, due to phylloquinone being
given with vitamin D and Ca rather than alone. For example,
Bolton-Smith et al.(27) reported a beneficial effect of phylloqui-
none supplementation (200mg/d) for 2 years on the BMD and
BMC of the ultradistal radius (but not of the mid-distal radius,
femoral neck or trochanter) in older healthy women but only
in conjunction with vitamin D and Ca and not when provided
alone and not when vitamin D and Ca were provided alone.
Braam et al.(31) showed that reduction of the BMD of the
femoral neck (but not of the lumbar spine) was significantly
less in a group of postmenopausal women supplemented
with phylloquinone (1000mg/d) plus Ca, vitamin D and Zn
than in the group who were given the same micronutrient
mix without phylloquinone or a placebo for 3 years.
Kanellakis et al.(32) have recently shown that low-dose phyllo-
quinone (100mg/d) together with vitamin D and Ca, in the
form of enriched dairy products, significantly lowered a
marker of bone resorption (urinary deoxypyridinoline) and
increased lumbar spine BMD in postmenopausal women
over 12 months compared with those who were given the
same dairy products enriched with vitamin D and Ca.
The amounts of vitamin D and Ca provided in the present
study were nutritional rather than therapeutic in nature. For
example, 500 mg/d of Ca and 10mg/d of vitamin D3 were pro-
vided to ensure that the relevant adequate intake levels
(1000–1200 mg/d and 5–10mg/d, respectively) for these nutri-
ents were met in all patients as defined at the time of the
study(35), which was before the publication of the 2011 Institute
of Medicine Dietary Reference Intake values for vitamin D
and Ca(36). Interestingly, even with 10mg/d of supplemental
vitamin D3 and a median habitual intake of 4·6mg/d, and thus
close to the new RDA for vitamin D of 15mg/d in the general
healthy adult population up to 70 years(32), 32 % of the CD
patients in thepresent studyhad serum25(OH)Dconcentrations
,50 nmol/l. Once Ca and vitamin D3 status was ensured, no
effect of phylloquinone supplementation was observed on the
concentrations of urinary NTx (a marker of bone resorption)
or other markers of bone turnover (serum CTx and BAP) in
the adult CD patients in the present study; this was so despite
reported correlations between serum ucOC and urinary NTx
concentrations in previous studies(13,14). This is the first study,
to our knowledge, to determine the effect of improving
vitamin K status on bone turnover in adult patients with CD.
The effect of phylloquinone supplementation (with and without
Ca and vitamin D) on the markers of bone turnover in RCT of
healthy adults has been very mixed, with some RCT finding
effects on some markers but not others(27,31,32) and effects
at some time points but not others(33), while some studies
found no effects at all(32).
It has been suggested that phylloquinone might have more
of an influence on more metabolically active skeletal sites
including those with a higher proportion of trabecular bone
compared with cortical bone(27). In the present study, several
skeletal sites were examined, including those that have been
reported to benefit from micronutrient intervention, but no
beneficial responses were observed, except for the total
radius. Even within the forearm, the ultradistal radius, which
has been suggested to be more responsive to intervention
effects(27), did not exhibit a beneficial response. However, it
should be stressed that while some studies have reported ben-
eficial effects of phylloquinone on bone mass indices after
1(32) or 2(27) years, some have shown that up to 3 years may
be needed to detect a positive effect of phylloquinone(31,37).
However, 12 months would have been ample time for changes
in bone turnover to have occurred.
Only patients with relatively good bone health were
enrolled in the present study and thus the effect of phyllo-
quinone supplementation on bone parameters in CD patients
with osteoporosis still deserves attention. Another limitation of
the study is the lack of reference serum phylloquinone con-
centration values from healthy adults to directly ascertain the
degree of vitamin K insufficiency in the patients with CD. In
relation to the analytical methodology used for the determi-
nation of %ucOC, it has been suggested that the enzyme
immunoassay method used for determining ucOC concen-
trations in the present study detects large osteocalcin
fragments (possibly arising from proteolysis in the circulation
or produced during sample processing and storage but may
also be a feature in individuals with high turnover states(38),
which has been reported in patients with CD(13,14)). The
%ucOC calculated in the present study expressed serum
ucOC as a percentage of total osteocalcin values (i.e. serum
ucOC þ serum cOC), and it is not clear whether the assay
for cOC likewise detects large osteocalcin fragments, in
which case the impact on %ucOC would be minimised.
In conclusion, the present study showed that phylloquinone
at a dose of 1000mg is sufficient to near-maximise the g-car-
boxylation status of osteocalcin in adult patients with CD
with long-standing disease and in clinical remission. Although
there are various lines of epidemiological evidence to support
an association between high under-g-carboxylated osteocalcin
status and poor bone health outcomes in patients with
CD(12–14,30), as in some studies in healthy subjects(39), the
clinical relevance of maximising the g-carboxylation status of
osteocalcin to skeletal health was not evident in the
12-month randomised, double-blind, placebo-controlled
intervention trial carried out in adult patients with CD in the
present study.
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